Flowchart of included RCTs of interleukin 6 (IL‐6) blocking agents (last search date 11 February 2021).
COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (Boutron 2020b). This review is a sub‐review of COVID‐NMA.
*two multiple‐arm RCTs evaluated both tocilizumab and sarilumab, one three‐arm RCT evaluated tocilizumab and siltuximab and consequently they appear twice. §one multi‐arm RCT evaluated both tocilizumab and sarilumab